2. Amyotrophic lateral sclerosis Clinical trials / Disease details
Clinical trials : 645 / Drugs : 589 - (DrugBank : 163) / Drug target genes : 150 - Drug target pathways : 225
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04518540 (ClinicalTrials.gov) | September 1, 2020 | 5/8/2020 | Explore Neuroprotective Effect of Lipoic Acid in Amyotrophic Lateral Sclerosis | Randomized, Parallel Safety and Efficacy Study of Lipoic Acid in Patients With Amyotrophic Lateral Sclerosis | Amyotrophic Lateral Sclerosis | Drug: lipoic acid group;Drug: control group | Second Affiliated Hospital, School of Medicine, Zhejiang University | NULL | Recruiting | 20 Years | 75 Years | All | 150 | N/A | China |
| 2 | NCT01363401 (ClinicalTrials.gov) | February 2011 | 30/5/2011 | Safety and Efficacy Study of Autologous Bone Marrow Derived Stem Cell Treatment in Amyotrophic Lateral Sclerosis | An Open-label, Phase I/II Trial for Safety and Efficacy Study of Autologous Bone Marrow Derived Stem Cell Treatment in Amyotrophic Lateral Sclerosis | Amyotrophic Lateral Sclerosis;ALS | Biological: HYNR-CS inj;Other: Control group | Corestem, Inc. | NULL | Completed | 25 Years | 75 Years | All | 72 | Phase 1/Phase 2 | Korea, Republic of |